Activity of Bevacizumab in Neuroendocrine Neoplasms

#2265

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Aim(s): To evaluate the efficacy and toxicity of BEV-containing protocols in NEN.

Materials and methods: We performed a retrospective analysis of all NEN patients who were treated with BEV-containing protocols at our center between August 2008 and November 2017.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,